Melatonin and agomelatine for preventing seasonal affective disorder

Angela Kaminski-Hartenthaler, Barbara Nussbaumer, Catherine A. Forneris, Laura C. Morgan, Bradley N. Gaynes, Jeffrey H. Sonis, Amy Greenblatt, Jörg Wipplinger, Linda J. Lux, Dietmar Winkler, Megan G. Van Noord, Julia Hofmann, Gerald Gartlehner

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Background: Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD in the United States ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on agomelatine and melatonin as preventive interventions. Objectives: To assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving patient-centred outcomes among adults with a history of SAD. Search methods: We conducted a search of the Specialised Register of the Cochrane Depression, Anxiety and Neurosis Review Group (CCDANCTR) to 11 August 2015. The CCDANCTR contains reports of relevant randomised controlled trials from EMBASE (1974 to date), MEDLINE (1950 to date), PsycINFO (1967 to date) and the Cochrane Central Register of Controlled Trials (CENTRAL). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Knowledge, The Cochrane Library and the Allied and Complementary Medicine Database (AMED) (to 26 May 2014). We conducted a grey literature search (e.g. in clinical trial registries) and handsearched the reference lists of all included studies and pertinent review articles. Selection criteria: To examine efficacy, we planned to include randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. To examine adverse events, we intended to include non-randomised studies. We planned to include studies that compared agomelatine versus melatonin, or agomelatine or melatonin versus placebo, any second-generation antidepressant (SGA), light therapy, psychological therapies or lifestyle changes. We also intended to compare melatonin or agomelatine in combination with any of the comparator interventions listed above versus the same comparator intervention as monotherapy. Data collection and analysis: Two review authors screened abstracts and full-text publications against the inclusion criteria. Two review authors planned to independently extract data and assess risk of bias of included studies. We planned to pool data for meta-analysis when participant groups were similar and when studies assessed the same treatments by using the same comparator and presented similar definitions of outcome measures over a similar duration of treatment; however, we identified no studies for inclusion. Main results: We identified 2986 citations through electronic searches and reviews of reference lists after de-duplication of search results. We excluded 2895 records during title and abstract review and assessed 91 articles at full-text level for eligibility. We identified no controlled studies on use of melatonin and agomelatine to prevent SAD and to improve patient-centred outcomes among adults with a history of SAD. Authors' conclusions: No available methodologically sound evidence indicates that melatonin or agomelatine is or is not an effective intervention for prevention of SAD and improvement of patient-centred outcomes among adults with a history of SAD. Lack of evidence clearly shows the need for well-conducted, controlled studies on this topic. A well-conducted RCT of melatonin or agomelatine for prevention of SAD would assess the comparative benefits and risks of these interventions against others currently used to treat the disorder.

Original languageEnglish (US)
Article numberCD011271
JournalCochrane Database of Systematic Reviews
Volume2015
Issue number11
DOIs
StatePublished - Nov 11 2015
Externally publishedYes

Fingerprint

S 20098
Seasonal Affective Disorder
Melatonin
Phototherapy
Randomized Controlled Trials
Antidepressive Agents
Life Style
Placebos
Psychology
Literature
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Kaminski-Hartenthaler, A., Nussbaumer, B., Forneris, C. A., Morgan, L. C., Gaynes, B. N., Sonis, J. H., ... Gartlehner, G. (2015). Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database of Systematic Reviews, 2015(11), [CD011271]. https://doi.org/10.1002/14651858.CD011271.pub2

Melatonin and agomelatine for preventing seasonal affective disorder. / Kaminski-Hartenthaler, Angela; Nussbaumer, Barbara; Forneris, Catherine A.; Morgan, Laura C.; Gaynes, Bradley N.; Sonis, Jeffrey H.; Greenblatt, Amy; Wipplinger, Jörg; Lux, Linda J.; Winkler, Dietmar; Van Noord, Megan G.; Hofmann, Julia; Gartlehner, Gerald.

In: Cochrane Database of Systematic Reviews, Vol. 2015, No. 11, CD011271, 11.11.2015.

Research output: Contribution to journalReview article

Kaminski-Hartenthaler, A, Nussbaumer, B, Forneris, CA, Morgan, LC, Gaynes, BN, Sonis, JH, Greenblatt, A, Wipplinger, J, Lux, LJ, Winkler, D, Van Noord, MG, Hofmann, J & Gartlehner, G 2015, 'Melatonin and agomelatine for preventing seasonal affective disorder', Cochrane Database of Systematic Reviews, vol. 2015, no. 11, CD011271. https://doi.org/10.1002/14651858.CD011271.pub2
Kaminski-Hartenthaler A, Nussbaumer B, Forneris CA, Morgan LC, Gaynes BN, Sonis JH et al. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database of Systematic Reviews. 2015 Nov 11;2015(11). CD011271. https://doi.org/10.1002/14651858.CD011271.pub2
Kaminski-Hartenthaler, Angela ; Nussbaumer, Barbara ; Forneris, Catherine A. ; Morgan, Laura C. ; Gaynes, Bradley N. ; Sonis, Jeffrey H. ; Greenblatt, Amy ; Wipplinger, Jörg ; Lux, Linda J. ; Winkler, Dietmar ; Van Noord, Megan G. ; Hofmann, Julia ; Gartlehner, Gerald. / Melatonin and agomelatine for preventing seasonal affective disorder. In: Cochrane Database of Systematic Reviews. 2015 ; Vol. 2015, No. 11.
@article{0152ffcdfc2c4de591f7d33171b5681d,
title = "Melatonin and agomelatine for preventing seasonal affective disorder",
abstract = "Background: Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD in the United States ranges from 1.5{\%} to 9{\%}, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on agomelatine and melatonin as preventive interventions. Objectives: To assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving patient-centred outcomes among adults with a history of SAD. Search methods: We conducted a search of the Specialised Register of the Cochrane Depression, Anxiety and Neurosis Review Group (CCDANCTR) to 11 August 2015. The CCDANCTR contains reports of relevant randomised controlled trials from EMBASE (1974 to date), MEDLINE (1950 to date), PsycINFO (1967 to date) and the Cochrane Central Register of Controlled Trials (CENTRAL). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Knowledge, The Cochrane Library and the Allied and Complementary Medicine Database (AMED) (to 26 May 2014). We conducted a grey literature search (e.g. in clinical trial registries) and handsearched the reference lists of all included studies and pertinent review articles. Selection criteria: To examine efficacy, we planned to include randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. To examine adverse events, we intended to include non-randomised studies. We planned to include studies that compared agomelatine versus melatonin, or agomelatine or melatonin versus placebo, any second-generation antidepressant (SGA), light therapy, psychological therapies or lifestyle changes. We also intended to compare melatonin or agomelatine in combination with any of the comparator interventions listed above versus the same comparator intervention as monotherapy. Data collection and analysis: Two review authors screened abstracts and full-text publications against the inclusion criteria. Two review authors planned to independently extract data and assess risk of bias of included studies. We planned to pool data for meta-analysis when participant groups were similar and when studies assessed the same treatments by using the same comparator and presented similar definitions of outcome measures over a similar duration of treatment; however, we identified no studies for inclusion. Main results: We identified 2986 citations through electronic searches and reviews of reference lists after de-duplication of search results. We excluded 2895 records during title and abstract review and assessed 91 articles at full-text level for eligibility. We identified no controlled studies on use of melatonin and agomelatine to prevent SAD and to improve patient-centred outcomes among adults with a history of SAD. Authors' conclusions: No available methodologically sound evidence indicates that melatonin or agomelatine is or is not an effective intervention for prevention of SAD and improvement of patient-centred outcomes among adults with a history of SAD. Lack of evidence clearly shows the need for well-conducted, controlled studies on this topic. A well-conducted RCT of melatonin or agomelatine for prevention of SAD would assess the comparative benefits and risks of these interventions against others currently used to treat the disorder.",
author = "Angela Kaminski-Hartenthaler and Barbara Nussbaumer and Forneris, {Catherine A.} and Morgan, {Laura C.} and Gaynes, {Bradley N.} and Sonis, {Jeffrey H.} and Amy Greenblatt and J{\"o}rg Wipplinger and Lux, {Linda J.} and Dietmar Winkler and {Van Noord}, {Megan G.} and Julia Hofmann and Gerald Gartlehner",
year = "2015",
month = "11",
day = "11",
doi = "10.1002/14651858.CD011271.pub2",
language = "English (US)",
volume = "2015",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Melatonin and agomelatine for preventing seasonal affective disorder

AU - Kaminski-Hartenthaler, Angela

AU - Nussbaumer, Barbara

AU - Forneris, Catherine A.

AU - Morgan, Laura C.

AU - Gaynes, Bradley N.

AU - Sonis, Jeffrey H.

AU - Greenblatt, Amy

AU - Wipplinger, Jörg

AU - Lux, Linda J.

AU - Winkler, Dietmar

AU - Van Noord, Megan G.

AU - Hofmann, Julia

AU - Gartlehner, Gerald

PY - 2015/11/11

Y1 - 2015/11/11

N2 - Background: Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD in the United States ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on agomelatine and melatonin as preventive interventions. Objectives: To assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving patient-centred outcomes among adults with a history of SAD. Search methods: We conducted a search of the Specialised Register of the Cochrane Depression, Anxiety and Neurosis Review Group (CCDANCTR) to 11 August 2015. The CCDANCTR contains reports of relevant randomised controlled trials from EMBASE (1974 to date), MEDLINE (1950 to date), PsycINFO (1967 to date) and the Cochrane Central Register of Controlled Trials (CENTRAL). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Knowledge, The Cochrane Library and the Allied and Complementary Medicine Database (AMED) (to 26 May 2014). We conducted a grey literature search (e.g. in clinical trial registries) and handsearched the reference lists of all included studies and pertinent review articles. Selection criteria: To examine efficacy, we planned to include randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. To examine adverse events, we intended to include non-randomised studies. We planned to include studies that compared agomelatine versus melatonin, or agomelatine or melatonin versus placebo, any second-generation antidepressant (SGA), light therapy, psychological therapies or lifestyle changes. We also intended to compare melatonin or agomelatine in combination with any of the comparator interventions listed above versus the same comparator intervention as monotherapy. Data collection and analysis: Two review authors screened abstracts and full-text publications against the inclusion criteria. Two review authors planned to independently extract data and assess risk of bias of included studies. We planned to pool data for meta-analysis when participant groups were similar and when studies assessed the same treatments by using the same comparator and presented similar definitions of outcome measures over a similar duration of treatment; however, we identified no studies for inclusion. Main results: We identified 2986 citations through electronic searches and reviews of reference lists after de-duplication of search results. We excluded 2895 records during title and abstract review and assessed 91 articles at full-text level for eligibility. We identified no controlled studies on use of melatonin and agomelatine to prevent SAD and to improve patient-centred outcomes among adults with a history of SAD. Authors' conclusions: No available methodologically sound evidence indicates that melatonin or agomelatine is or is not an effective intervention for prevention of SAD and improvement of patient-centred outcomes among adults with a history of SAD. Lack of evidence clearly shows the need for well-conducted, controlled studies on this topic. A well-conducted RCT of melatonin or agomelatine for prevention of SAD would assess the comparative benefits and risks of these interventions against others currently used to treat the disorder.

AB - Background: Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD in the United States ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on agomelatine and melatonin as preventive interventions. Objectives: To assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving patient-centred outcomes among adults with a history of SAD. Search methods: We conducted a search of the Specialised Register of the Cochrane Depression, Anxiety and Neurosis Review Group (CCDANCTR) to 11 August 2015. The CCDANCTR contains reports of relevant randomised controlled trials from EMBASE (1974 to date), MEDLINE (1950 to date), PsycINFO (1967 to date) and the Cochrane Central Register of Controlled Trials (CENTRAL). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Knowledge, The Cochrane Library and the Allied and Complementary Medicine Database (AMED) (to 26 May 2014). We conducted a grey literature search (e.g. in clinical trial registries) and handsearched the reference lists of all included studies and pertinent review articles. Selection criteria: To examine efficacy, we planned to include randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. To examine adverse events, we intended to include non-randomised studies. We planned to include studies that compared agomelatine versus melatonin, or agomelatine or melatonin versus placebo, any second-generation antidepressant (SGA), light therapy, psychological therapies or lifestyle changes. We also intended to compare melatonin or agomelatine in combination with any of the comparator interventions listed above versus the same comparator intervention as monotherapy. Data collection and analysis: Two review authors screened abstracts and full-text publications against the inclusion criteria. Two review authors planned to independently extract data and assess risk of bias of included studies. We planned to pool data for meta-analysis when participant groups were similar and when studies assessed the same treatments by using the same comparator and presented similar definitions of outcome measures over a similar duration of treatment; however, we identified no studies for inclusion. Main results: We identified 2986 citations through electronic searches and reviews of reference lists after de-duplication of search results. We excluded 2895 records during title and abstract review and assessed 91 articles at full-text level for eligibility. We identified no controlled studies on use of melatonin and agomelatine to prevent SAD and to improve patient-centred outcomes among adults with a history of SAD. Authors' conclusions: No available methodologically sound evidence indicates that melatonin or agomelatine is or is not an effective intervention for prevention of SAD and improvement of patient-centred outcomes among adults with a history of SAD. Lack of evidence clearly shows the need for well-conducted, controlled studies on this topic. A well-conducted RCT of melatonin or agomelatine for prevention of SAD would assess the comparative benefits and risks of these interventions against others currently used to treat the disorder.

UR - http://www.scopus.com/inward/record.url?scp=84959373038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959373038&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD011271.pub2

DO - 10.1002/14651858.CD011271.pub2

M3 - Review article

C2 - 26560173

AN - SCOPUS:84959373038

VL - 2015

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 11

M1 - CD011271

ER -